IRF1 and neoplasm: The IFN-γ–IFNGR1/2–JAK1/2–STAT1–IRF1 axis is central to anti-tumor immunity, and dysregulation of this pathway can perturb PD-L1 levels and alter sensitivity to immunotherapy [134,135,136].